

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.	50474/017002
Serial No.	10/626,914
Applicant	Anan Chuntharapai et al.
Filing Date	July 25, 2003
Group	1644
IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	3,773,919	Nov. 20, 1973	Boswell et al.
	4,179,337	Dec. 18, 1979	Davis et al.
	4,301,144	Nov. 17, 1981	Iwashita et al.
	4,496,689	Jan. 29, 1985	Mitra
	4,640,835	Feb. 3, 1987	Shimizu et al.
	4,670,417	Jun. 2, 1987	Iwasaki et al.
	4,791,192	Dec. 13, 1988	Nakagawa et al.
	4,816,567	Mar. 28, 1989	Cabilly et al.
	4,861,579	Aug. 29, 1989	Meyer et al.
	5,182,196	Jan. 26, 1993	Allet et al.
	5,262,309	Nov. 16, 1993	Nakamura et al.
	5,422,104	Jun. 6, 1995	Fiers et al.
	5,428,130	Jun. 27, 1995	Capon et al.
	5,486,463	Jan. 23, 1996	Lesslauer et al.
	5,500,362	Mar. 19, 1996	Robinson et al.
	5,519,119	May 21, 1996	Yamada et al.
	5,540,926	Jul. 30, 1996	Aruffo et al.
	5,587,457	Dec. 24, 1996	Rathjen et al.
	5,595,721	Jan. 21, 1997	Kaminski et al.
	5,610,279	Mar. 11, 1997	Brockhaus et al.
	5,641,663	Jun. 24, 1997	Garvin et al.
EXAMINER			DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS			
	5,652,353	Jul. 29, 1997	Fiers et al.
	5,677,180	Oct. 14, 1997	Robinson et al.
	5,721,108	Feb. 24, 1998	Robinson et al.
	5,736,137	Apr. 7, 1998	Anderson et al.
	5,776,456	Jul. 7, 1998	Anderson et al.
	5,808,029	Sep. 15, 1998	Brockhaus et al.
	5,821,337	Oct. 13, 1998	Carter et al.
	5,843,398	Dec. 1, 1998	Kaminski et al.
	5,843,439	Dec. 1, 1998	Anderson et al.
	5,849,898	Dec. 15, 1998	Seed et al.
	6,015,542	Jan. 18, 2000	Kaminski et al.
	6,090,365	Jul. 18, 2000	Kaminski et al.
	6,120,767	Sep. 19, 2000	Robinson et al.
	6,171,586	Jan. 9, 2001	Lam et al.
	6,171,787	Jan. 9, 2001	Wiley
	6,194,551	Feb. 27, 2001	Idusogie et al.
	6,224,866	May 1, 2001	Barbera-Guillem
	6,242,195	Jun. 5, 2001	Idusogie et al.
	6,287,537	Sep. 11, 2001	Kaminski et al.
	6,297,022	Oct. 2, 2001	McDonnell et al.
	6,297,367	Oct. 2, 2001	Tribouley
	6,306,393	Oct. 23, 2001	Goldenberg
	6,355,782	Mar. 12, 2002	Zonana et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS			
	6,368,596	Apr. 9, 2002	Ghetie et al.
	6,399,061	Jun. 4, 2002	Anderson et al.
	6,403,770	Jun. 11, 2002	Yu et al.
	6,410,391	Jun. 25, 2002	Zelsacher
	6,440,694	Aug. 27, 2002	Bienkowski et al.
	6,455,043	Sep. 24, 2002	Grillo-Lopez
	6,475,986	Nov. 5, 2002	Aggarwal
	6,475,987	Nov. 5, 2002	Shu
	6,506,882	Jan. 14, 2003	Yu et al.
	6,509,170	Jan. 21, 2003	Yu et al.
	6,528,624	Mar. 4, 2003	Idusogie et al.
	6,538,124	Mar. 25, 2003	Idusogie et al.
	6,541,224	Apr. 1, 2003	Yu et al.
	6,551,795	Apr. 22, 2003	Rubenfield et al.
	6,565,827	May 20, 2003	Kaminski et al.
	6,652,852	Nov. 25, 2003	Robinson et al.
	6,682,734	Jan. 27, 2004	Anderson et al.
	6,869,605	Mar. 22, 2005	Browning et al.
	6,875,846	Apr. 5, 2005	Rennert et al.
	7,083,785	Aug. 1, 2006	Browning et al.
	2001/0018041	Aug. 30, 2001	Hanna et al.
	2002/0004587	Jan. 10, 2002	Miller et al.
	2002/0006404	Jan. 17, 2002	Hanna et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50474/017002
	Serial No.	10/626,914
	Applicant	Anan Chuntharapai et al.
	Filing Date	July 25, 2003
	Group	1644
	IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS			
	2002/0009427	Jan. 24, 2002	Wolin et al.
	2002/0009444	Jan. 24, 2002	Grillo-Lopez
	2002/0012665	Jan. 31, 2002	Hanna
	2002/0037852	Mar. 28, 2002	Browning et al.
	2002/0041847	Apr. 11, 2002	Goldenberg
	2002/0058029	May 16, 2002	Hanna
	2002/0081296	Jun. 27, 2002	Theill et al.
	2002/0086018	Jul. 4, 2002	Theill et al.
	2002/0128488	Sep. 12, 2002	Yamakawa et al.
	2002/0136719	Sep. 26, 2002	Shenoy et al.
	2002/0165156	Nov. 7, 2002	Browning et al.
	2002/0172674	Nov. 21, 2002	Browning et al.
	2002/0197255	Dec. 26, 2002	Anderson et al.
	2002/0197256	Dec. 26, 2002	Grewal
	2003/0012783	Jan. 16, 2003	Kindsvogel
	2003/0021781	Jan. 30, 2003	Anderson et al.
	2003/0023038	Jan. 30, 2003	Rennert et al.
	2003/0026801	Feb. 6, 2003	Weiner et al.
	2003/0068664	Apr. 10, 2003	Albitar et al.
	2003/0082172	May 1, 2003	Anderson et al.
	2003/0082175	May 1, 2003	Schneider et al.
	2003/0092164	May 15, 2003	Gross et al.
	2003/0095963	May 22, 2003	Anderson et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS			
	2003/0095967	May 22, 2003	MacKay et al.
	2003/0099990	May 29, 2003	Hsu
	2003/0103971	Jun. 5, 2003	Hariharan et al.
	2003/0133930	Jul. 17, 2003	Goldenberg et al.
	2003/0147885	Aug. 7, 2003	Anderson et al.
	2003/0157108	Aug. 21, 2003	Presta
	2003/0180292	Sep. 25, 2003	Hanna et al.
	2003/0185796	Oct. 2, 2003	Wolin et al.
	2003/0194743	Oct. 16, 2003	Beltzer et al.
	2003/0219433	Nov. 27, 2003	Hansen et al.
	2003/0219818	Nov. 27, 2003	Bohen et al.
	2004/0093621	May 13, 2004	Shitara et al.
	2005/0070689	Mar. 31, 2005	Dixit et al.
	2005/0095243	May 5, 2005	Chan et al.
	2005/0163775	Jul. 28, 2005	Chan et al.
	2006/0073146	Apr. 6, 2006	Ashkenazi et al.
	2006/0240517	Oct. 26, 2006	Ambrose et al.
	2006/0240519	Oct. 26, 2006	Ambrose et al.
	2006/0240520	Oct. 26, 2006	Ambrose et al.
	2007/24,344	Nov. 28, 2008	Ashkenazi et al.

US applications are not published US Patent documents and should be listed under "other documents".

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	0 307 247 A2	Mar. 15, 1989	EPO	
	0 330 199 A1	Aug. 30, 1989	EPO	
	0 332 865 A2	Sep. 20, 1989	EPO	
	0 417 563 B1	Mar. 3, 1990	EPO	
	0 869 180 A1	Oct. 7, 1998	EPO	
	0 870 827 A2	Oct. 14, 1998	EPO	
	0 911 633 A1	Apr. 28, 1999	EPO	
	WO 95/03770 A1	Feb. 9, 1995	WIPO	
	WO 97/01633 A1	Jan. 16, 1997	WIPO	
	WO 97/25428 A1	Jul. 17, 1997	WIPO	
	WO 97/33902 A1	Sep. 18, 1997	WIPO	
	WO 98/18921 A1	May 7, 1998	WIPO	
	WO 98/27114 A2	Jun. 25, 1998	WIPO	
	WO 98/28426 A2	Jul. 2, 1998	WIPO	
	WO 98/32856 A1	Jul. 30, 1998	WIPO	
	WO 98/35986 A1	Aug. 20, 1998	WIPO	
	WO 98/41629 A2	Sep. 24, 1998	WIPO	
	WO 98/46643 A1	Oct. 22, 1998	WIPO	
	WO 98/46751 A1	Oct. 22, 1998	WIPO	
	WO 98/51793 A1	Nov. 19, 1998	WIPO	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	WO 98/55620 A1	Dec. 10, 1998	WIPO	
	WO 98/55621 A1	Dec. 10, 1998	WIPO	
	WO 98/56418 A1	Dec. 17, 1998	WIPO	
	WO 98/58964 A1	Dec. 30, 1998	WIPO	
	WO 99/00518 A1	Jan. 7, 1999	WIPO	
	WO 99/02653 A1	Jan. 21, 1999	WIPO	
	WO 99/04001 A1	Jan. 28, 1999	WIPO	
	WO 99/07738 A2	Feb. 18, 1999	WIPO	
	WO 99/09165 A1	Feb. 25, 1999	WIPO	
	WO 99/11791 A2	Mar. 11, 1999	WIPO	
	WO 99/12964 A2	Mar. 18, 1999	WIPO	
	WO 99/12965 A2	Mar. 18, 1999	WIPO	
	WO 99/19490 A1	Apr. 22, 1999	WIPO	
	WO 99/22764 A1	May 14, 1999	WIPO	
	WO 99/28462 A2	Jun. 10, 1999	WIPO	
	WO 99/33980 A2	Jul. 8, 1999	WIPO	
	WO 99/33988 A1	Jul. 8, 1999	WIPO	
	WO 99/35170 A2	Jul. 15, 1999	WIPO	
	WO 99/50416 A1	Oct. 7, 1999	WIPO	
	WO 99/51642 A1	Oct. 14, 1999	WIPO	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	WO 00/09160 A1	Feb. 24, 2000	WIPO	
	WO 00/20864 A1	Apr. 13, 2000	WIPO	
	WO 00/24811 A1	May 4, 2000	WIPO	
	WO 00/26244 A2	May 11, 2000	WIPO	
	WO 00/27428 A1	May 18, 2000	WIPO	
	WO 00/27433 A1	May 18, 2000	WIPO	
	WO 00/39295 A1	Jul. 6, 2000	WIPO	
	WO 00/42072 A2	Jul. 20, 2000	WIPO	
	WO 00/43032 A2	Jul. 27, 2000	WIPO	
	WO 00/44788 A1	Aug. 3, 2000	WIPO	
	WO 00/45836 A1	Aug. 10, 2000	WIPO	
	WO 00/50597 A2	Aug. 31, 2000	WIPO	
	WO 00/50633 A1	Aug. 31, 2000	WIPO	
	WO 00/58362 A1	Oct. 5, 2000	WIPO	
	WO 00/67795 A1	Nov. 16, 2000	WIPO	
	WO 00/67796 A1	Nov. 16, 2000	WIPO	
	WO 00/68378 A1	Nov. 16, 2000	WIPO	
	WO 00/74718 A1	Dec. 14, 2000	WIPO	
	WO 00/76542 A1	Dec. 21, 2000	WIPO	
	WO 01/03734 A1	Jan. 18, 2001	WIPO	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	WO 01/10460 A1	Feb. 15, 2001	WIPO	
	WO 01/10461 A1	Feb. 15, 2001	WIPO	
	WO 01/10462 A1	Feb. 15, 2001	WIPO	
	WO 01/12812 A2	Feb. 22, 2001	WIPO	
	WO 01/13945 A1	Mar. 1, 2001	WIPO	
	WO 01/24811 A1	Apr. 12, 2001	WIPO	
	WO 01/25256 A2	Apr. 12, 2001	WIPO	
	WO 01/34194 A1	May 17, 2001	WIPO	
	WO 01/58949 A2	Aug. 16, 2001	WIPO	
	WO 01/60397 A1	Aug. 23, 2001	WIPO	
	WO 01/72333 A1	Oct. 4, 2001	WIPO	
	WO 01/74388 A1	Oct 11, 2001	WIPO	
	WO 01/77342 A1	Oct. 18, 2001	WIPO	
	WO 01/80844 A2	Nov. 1, 2001	WIPO	
	WO 01/96528 A2	Dec. 20, 2001	WIPO	
	WO 01/97858 A2	Dec. 27, 2001	WIPO	
	WO 02/02641 A1	Jan. 10, 2002	WIPO	
	WO 02/04021 A1	Jan. 17, 2002	WIPO	
	WO 02/16312 A2	Feb. 28, 2002	WIPO (English language abstract)	
	WO 02/16412 A2	Feb. 28, 2002	WIPO	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.~~ /R.S./

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	WO 02/18620 A2	Mar. 7, 2002	WIPO	
	WO 02/24909 A2	Mar. 28, 2002	WIPO	
	WO 02/34790 A1	May 2, 2002	WIPO	
	WO 02/38766 A2	May 16, 2002	WIPO	
	WO 02/060485 A2	Aug. 8, 2002	WIPO	
	WO 02/060955 A2	Aug. 8, 2002	WIPO	
	WO 02/079255 A1	Oct. 10, 2002	WIPO	
	WO 02/092620 A2	Nov. 21, 2002	WIPO	
	WO 02/094192 A2	Nov. 28, 2002	WIPO	
	WO 02/094852 A2	Nov. 28, 2002	WIPO	
	WO 02/096948 A2	Dec. 5, 2002	WIPO	
	WO 02/102312 A2	Dec. 27, 2002	WIPO	
	WO 03/002607 A1	Jan. 9, 2003	WIPO	
	WO 03/014294 A2	Feb. 20, 2003	WIPO	
	WO 03/024991 A2	Mar. 27, 2003	WIPO	
	WO 03/033658 A2	Apr. 24, 2003	WIPO	
	WO 03/035846 A2	May 1, 2003	WIPO	
	WO 03/045421 A1	Jun. 5, 2003	WIPO	
	WO 03/049694 A2	Jun. 19, 2003	WIPO	
	WO 03/055979 A2	Jul. 10, 2003	WIPO	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	WO 03/061694 A1	Jul. 31, 2003	WIPO	
	WO 03/068821 A2	Aug. 21, 2003	WIPO	
	WO 2004/011611 A2	Feb. 5, 2004	WIPO	
	WO 2004/032828 A2	Apr. 22, 2004	WIPO	
	WO 2004/035607 A2	Apr. 29, 2004	WIPO	
	WO 2004/056312 A2	Jul. 8, 2004	WIPO	
	WO 2004/081043 A2	Sep. 23, 2004	WIPO	
	WO 2005/000351 A2	Jan. 6, 2005	WIPO	
	WO 2005/005462 A2	Jan. 20, 2005	WIPO	
	WO 2006/052493 A1	May 18, 2006	WIPO	
	WO 2006/068867 A1	May 29, 2006	WIPO	
	WO 2006/073941 A2	Jul. 13, 2006	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Allen et al., "CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome," <i>Science</i> 259:990-3 (1993).
	Amakawa et al., "The Hodgkin disease antigen CD30 is crucial for antigen induced death of developing T cells," <i>Cold Spring Harbor Laboratory Symposium on Programmed Cell Death</i> , Abstract No. 10 (1995).
	Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation," <i>Blood</i> 63:1424-33 (1984).
	Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function," <i>Nature</i> 390:175-9 (1997).
	Anolik and Aringer, "New treatments for SLE: cell-depleting and anti-cytokine therapies," <i>Best Pract. Res. Clin. Rheumatol.</i> 19:859-78 (2005).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.~~ /R.S./

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50474/017002
	Serial No.	10/626,914
	Applicant	Anan Chuntharapai et al.
	Filing Date	July 25, 2003
	Group	1644
	IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Armitage et al., "Molecular and biological characterization of a murine ligand for CD40," <i>Nature</i> 357:80-2 (1992).
	Arufo et al., "CD44 is the principal cell surface receptor for hyaluronate," <i>Cell</i> 61:1303-13 (1990).
	Arufo et al., "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome," <i>Cell</i> 72:291-300 (1993).
	Ashkenazi and Dixit, "Death receptors: signaling and modulation," <i>Science</i> 281:1305-8 (1998).
	Ashkenazi et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," <i>Proc. Natl. Acad. Sci. USA</i> 88:10535-9 (1991).
	Bachmann et al., "TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation," <i>J. Exp. Med.</i> 189:1025-31 (1999).
	Baldwin, "The NF- κ B and I κ B proteins: new discoveries and insights," <i>Annu. Rev. Immunol.</i> 14:649-83 (1996).
	Banner et al., "Crystal structure of the soluble human 55 kd TNF receptor-human TNF β complex: implications for TNF receptor activation," <i>Cell</i> 73:431-45 (1993).
	Barbas et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity," <i>Proc. Natl. Acad. Sci. USA</i> 91:3809-13 (1994).
	Batten et al., "BAFF mediates survival of peripheral immature B lymphocytes," <i>J. Exp. Med.</i> 192:1453-65 (2000).
	Bodmer et al., "TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88 (1997).
	Bodmer et al., "The molecular architecture of the TNF superfamily," <i>Trends Biochem. Sci.</i> 27:19-26 (2002).
	Bost and Pascual, "Antibodies against a peptide sequence within the HIV envelope protein cross reacts with human interleukin-2," <i>Immunol. Invest.</i> 17:577-86 (1988).
	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 87:3127-31 (1990).
	Brojatsch et al., "CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis," <i>Cell</i> 87:845-55 (1996).
	Browning et al., "Lymphotoxin β , a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface," <i>Cell</i> 72:847-56 (1993).
	Callard et al., "CD40 ligand and its role in X-linked hyper-IgM syndrome," <i>Immunol. Today</i> 14:559-64 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50474/017002
	Serial No.	10/626,914
	Applicant	Anan Chuntharapai et al.
	Filing Date	July 25, 2003
	Group	1644
	IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Cathcart et al., "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," <i>Lab. Invest.</i> 54:26-31 (1986).
	Chamow and Ashkenazi, "Immunoadhesins: principles and applications," <i>Trends Biotechnol.</i> 14:52-60 (1996).
	Cheema et al., "Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases," <i>Arthritis Rheum.</i> 44:1313-9 (2001).
	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis," <i>J. Biol. Chem.</i> 272:32401-10 (1997).
	Chinnaiyan et al., "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95," <i>Science</i> 274:990-2 (1996).
	Clark and Ledbetter, "Structure, function, and genetics of human B cell-associated surface molecules," <i>Adv. Cancer Res.</i> 52:81-149 (1989).
	Courtenay et al., "Immunisation against heterologous type II collagen induces arthritis in mice," <i>Nature</i> 283:666-8 (1980).
	Cragg et al., "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts," <i>Blood</i> 101:1045-52 (2003).
	Craxton et al., "A role for zTNF4/APRIL in the co-stimulation of B cell proliferation by macrophages," <i>Experimental Biology 2002: Meeting Abstracts</i> , Abstract 516.51:A704-5 (2002).
	Cyster, "B cells on the front line," <i>Nat. Immunol.</i> 1:9-10 (2000).
	Dealtry et al., "DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon- γ ," <i>Eur. J. Immunol.</i> 17:689-93 (1987).
	Degli-Esposti et al., "The novel receptor TRAIL-R4 induces NF- κ B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain," <i>Immunity</i> 7:813-20 (1997).
	Degli-Esposti et al., "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family," <i>J. Exp. Med.</i> 186:1165-70 (1997).
	De Vita et al., "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells," <i>Arthritis Rheum.</i> 46:2029-33 (2002).
	Do et al., "Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response," <i>J. Exp. Med.</i> 192:953-64 (2000).
	Domingues, "Rational design strategies to improve cytokine foldability and minimization of a functional motif: the IL-4 case," Thesis, University of Utrecht, p. 48, line 25 through p. 51, line 6; page 94, Table III (May 26, 1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	<table> <tr> <td>Attorney Docket No.</td> <td>50474/017002</td> </tr> <tr> <td>Serial No.</td> <td>10/626,914</td> </tr> <tr> <td>Applicant</td> <td>Anan Chuntharapai et al.</td> </tr> <tr> <td>Filing Date</td> <td>July 25, 2003</td> </tr> <tr> <td>Group</td> <td>1644</td> </tr> <tr> <td>IDS Filed</td> <td>August 7, 2008</td> </tr> </table>	Attorney Docket No.	50474/017002	Serial No.	10/626,914	Applicant	Anan Chuntharapai et al.	Filing Date	July 25, 2003	Group	1644	IDS Filed	August 7, 2008
Attorney Docket No.	50474/017002												
Serial No.	10/626,914												
Applicant	Anan Chuntharapai et al.												
Filing Date	July 25, 2003												
Group	1644												
IDS Filed	August 7, 2008												

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Durie et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," <i>Science</i> 261:1328-30 (1993).
	Durie et al., "The role of CD40 in the regulation of humoral and cell-mediated immunity," <i>Immunol. Today</i> 15:406-11 (1994).
	Edwards et al., "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes," <i>Rheumatology</i> 40:205-11 (2001).
	Edwards et al., "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders," <i>Biochemical Society Transactions</i> 30:824-8 (2002).
	Edwards et al., "Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo controlled trial in patients with rheumatoid arthritis," <i>Arthritis Rheum.</i> 446:S197 (2002).
	Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL," <i>J. Biol. Chem.</i> 273:14363-7 (1998).
	Flanagan and Leder, "The <i>kit</i> ligand: a cell surface molecule altered in steel mutant fibroblasts," <i>Cell</i> 63:185-94 (1990).
	Foy et al., "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory," <i>J. Exp. Med.</i> 180:157-63 (1994).
	Foy et al., "Immune regulation by CD40 and its ligand GP39," <i>Annu. Rev. Immunol.</i> 14:591-617 (1996).
	Francisco et al., "In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40," <i>Blood</i> 89:4493-500 (1997).
	Fütterer et al., "The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues," <i>Immunity</i> 9:59-70 (1998).
	GenBank accession number AF046888
	GenBank accession number AF136293
	GenBank accession number AK008142
	GenBank accession number AI250289, XP002206618
	GenBank accession number Z99716.4, XP002206619
	Glennie and van de Winkel, "Renaissance of cancer therapeutic antibodies," <i>Drug Discov. Today</i> 8:503-10 (2003).
	Golstein, "Cell death: TRAIL and its receptors," <i>Curr. Biol.</i> 7:R750-3 (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Goodwin et al., "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor," <i>Cell</i> 73:447-56 (1993).
	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," <i>Mol. Cell. Biol.</i> 11:3020-6 (1991).
	Goodwin et al., "Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor," <i>Eur. J. Immunol.</i> 23:2631-41 (1993).
	Gordon et al., "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site," <i>Biochemistry</i> 42:5977-83 (2003).
	Gorman et al., "B cell depletion in autoimmune disease," <i>Arthritis Res. Ther.</i> 5:S17-21 (2003).
	Gras et al., "BCMAP: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes," <i>Int. Immunol.</i> 7:1093-106 (1995).
	Gray, "Recruitment of virgin B cells into an immune response is restricted to activation outside lymphoid follicles," <i>Immunology</i> 65:73-9 (1988).
	Green and Flavell, "TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation," <i>J. Exp. Med.</i> 189:1017-20 (1999).
	Grewal et al., "Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis," <i>Science</i> 273:1864-7 (1996).
	Groom et al., "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome," <i>J. Clin. Invest.</i> 109:59-68 (2002).
	Gruss and Dower, "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas," <i>Blood</i> 85:3378-404 (1995).
	Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth," <i>J. Exp. Med.</i> 188:1185-90 (1998).
	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in <i>E. coli</i> ," <i>J. Cell. Biochem.</i> (abstract only) Supplement 15F:113 (P424) (1991).
	Han et al., "Cellular interaction in germinal centers: roles of CD40 ligand and B7-2 in established germinal centers," <i>J. Immunol.</i> 155:556-67 (1995).
	Hansen et al., "Genetic profile of insertion mutations in mouse leukemias and lymphomas," <i>Genome Res.</i> 10:237-43 (2000).
	Harbury et al., "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants," <i>Science</i> 262:1401-7 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

nonconsidered references are missing inventor names and date application filed.

Sheet 16 of 26

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50474/017002
	Serial No.	10/626,914
	Applicant	Anan Chuntharapai et al.
	Filing Date	July 25, 2003
	Group	1644
	IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," <i>Science</i> 262:905-7 (1993).
	Hawkins et al., "Selection of phage antibodies by binding affinity: mimicking affinity maturation," <i>J. Mol. Biol.</i> 226:889-96 (1992).
	Higashida et al., "Treatment of DMARD-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
	Hoag et al., "A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15," <i>Immunogenetics</i> 51:924-9 (2000).
	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)," <i>J. Biol. Chem.</i> 264:14927-34 (1989).
	Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," <i>Agents Actions</i> 19:295-305 (1986).
	Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," <i>Science</i> 253:1278-80 (1991).
	Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," <i>Mol. Immunol.</i> 28:1027-37 (1991).
	Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor 5," <i>Mol. Cell</i> 4:563-71 (1999).
	Hymowitz et al., "Structures of APRIL-receptor complexes," <i>J. Biol. Chem.</i> 280:7218-27 (2005).
	Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," <i>J. Immunol.</i> 164:4178-84 (2000).
	International Search Report for International Application No. PCT/US00/52976, mailed Jun. 11, 2001.
	International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2002.
	International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006.
	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," <i>Cell</i> 66:233-43 (1991).
	Jackson et al., "In vitro antibody maturation: improvement of a high affinity, neutralizing antibody against IL-1 β ," <i>J. Immunol.</i> 154:3310-9 (1995).
	Johnson et al., "Expression and structure of the human NGF receptor," <i>Cell</i> 47:545-54 (1986).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Johnson and Chiswell, "Human antibody engineering," <i>Curr. Opin. Struc. Biol.</i> 3:564-71 (1993).
	Joosten et al., "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNF α , anti-IL-1 α/β , and IL-1Ra," <i>Arthritis Rheum.</i> 39:797-809 (1996).
	Josien et al., "TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).
	Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).
	Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders," <i>Expert Opin. Ther. Targets</i> 7:115-23 (2003).
	Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).
	Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formation," <i>J. Immunol.</i> 160:4788-95 (1998).
	Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation," <i>Immunity</i> 1:167-78 (1994).
	Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF- κ B2," <i>Immunity</i> 10:515-24 (2002).
	Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," <i>Cancer Res.</i> 60:1021-7 (2000).
	Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> 97:3370-5 (2000).
	Khare and Hsu, "The role of TALL-1 and APRIL in immune regulation," <i>Trends Immunol.</i> 22:61-3 (2001).
	Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytotoxicity," <i>Leuk. Res.</i> 11:1119-25 (1987).
	Kim et al., "Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA," <i>J. Immunol. Methods</i> 156:9-17 (1992).
	Kitson et al., "A death-domain-containing receptor that mediates apoptosis," <i>Nature</i> 384:372-5 (1996).
	Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-5 (1990).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/626,914
(37 C.F.R. § 1.98(b))		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Kong et al., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> 397:315-23 (1999).
	Kong et al., "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand," <i>Nature</i> 402:304-9 (1999).
	Krammer et al., "Regulation of apoptosis in the immune system," <i>Curr. Opin. Immunol.</i> 6:279-89 (1994).
	Kwon et al., "Single amino acid substitutions of α_1 -antitrypsin that confer enhancement in thermal stability," <i>J. Biol. Chem.</i> 269:9627-31 (1994).
	Kwon et al., "Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes," <i>Curr. Opin. Immunol.</i> 11:340-5 (1999).
	Laabi and Strasser, "Lymphocyte survival – ignorance is BlyS," <i>Science</i> 289:883-4 (2000).
	Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma," <i>EMBO J.</i> 11:3897-904 (1992).
	Laabi et al., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed," <i>Nucleic Acids Res.</i> 22:1147-54 (1994).
	Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," <i>Cell</i> 93:165-76 (1998).
	Lane et al., "B cell function in mice transgenic for mCTLA-Hy1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4 ⁺ T cells," <i>J. Exp. Med.</i> 179:819-30 (1994).
	Leandro et al., "An open study of B lymphocyte depletion in systemic lupus erythematosus," <i>Arthritis Rheum.</i> 46:2673-7 (2002).
	Leandro et al., "B lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response," <i>Arthritis Rheum.</i> 44:S370, Abstract No. 1905 (2001).
	Leandro et al., "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion," <i>Ann. Rheum. Dis.</i> 61:883-8 (2002).
	Ledbetter et al., "Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5," <i>Crit. Rev. Immunol.</i> 17:427-35 (1997).
	Lenschow et al., "CD28/B7 system of T cell costimulation," <i>Annu. Rev. Immunol.</i> 14:233-58 (1996).
	Lentz et al., "Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse," <i>J. Immunol.</i> 157:598-606 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No. 50474/017002
	Serial No. 10/626,914
	Applicant Anan Chuntharapai et al.
	Filing Date July 25, 2003
	Group 1644
	IDS Filed August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Lentz et al., "Bcmd decreases the life span of B-2 but not B-1 cells in AWySnJ mice," <i>J. Immunol.</i> 160:3743-7 (1998).
	Lesley et al., "Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF," <i>Immunity</i> 20:441-53 (2004).
	Levine and Pestronk, "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab," <i>Neurology</i> 52:1701-4 (1999).
	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific," <i>Proc. Natl. Acad. Sci. USA</i> 88:2830-4 (1991).
	Linsley et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule," <i>Science</i> 257:792-5 (1992).
	Locksley et al., "The TNF and TNF receptor superfamilies: integrating mammalian biology," <i>Cell</i> 104:487-501 (2001).
	Loetscher et al., "Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor," <i>Cell</i> 61:351-9 (1990).
	Lotz et al., "The nerve growth factor/tumor necrosis factor receptor family," <i>J. Leukocyte Biol.</i> 60:1-7 (1996).
	MacFarlane et al., "Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL," <i>J. Biol. Chem.</i> 272:25417-20 (1997).
	Mackay and Browning, "BAFF: a fundamental survival factor for B cells," <i>Nature Rev. Immunol.</i> 2:465-75 (2002).
	Mackay et al., "Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations," <i>J. Exp. Med.</i> 190:1697-710 (1999).
	Mackay et al., "BAFF and APRIL: a tutorial on B cell survival," <i>Annu. Rev. Immunol.</i> 21:231-64 (2003).
	MacLennan, "Germinal centers," <i>Annu. Rev. Immunol.</i> 12:117-39 (1994).
	Madry et al., "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily," <i>Int. Immunol.</i> 10:1693-702 (1998).
	Maini et al., "Monoclonal anti-TNF α antibody as a probe of pathogenesis and therapy of rheumatoid disease," <i>Immunol. Rev.</i> 144:195-223 (1995).
	Mallett et al., "Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes – a molecule related to nerve growth factor receptor," <i>EMBO J.</i> 9:1063-8 (1990).
	Mandala et al., "Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists," <i>Science</i> 296:346-9 (2002).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Marsters et al., "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF- κ B," <i>Curr. Biol.</i> 6:1669-76 (1996).
	Marsters et al., "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates transcription factors NF- κ B and AP-1," <i>J. Biol. Chem.</i> 272:14029-32 (1997).
	Marsters et al., "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," <i>Curr. Biol.</i> 6:750-2 (1996).
	Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," <i>Curr. Biol.</i> 7:1003-6 (1997).
	Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," <i>Curr. Biol.</i> 8:525-8 (1998).
	Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," <i>Curr. Biol.</i> 10:785-8 (2000).
	Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin- α -deficient mice," <i>Nature</i> 382:462-6 (1996).
	Matthews, "Medical heretics," <i>New Scientist</i> 170:34-7 (2001).
	Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator," <i>Immunity</i> 8:21-30 (1998).
	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552-4 (1990).
	McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69 th Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Health Professionals, Oral Presentation #1920 (November 16, 2005).
	Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).
	Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," <i>Cell</i> 87:427-36 (1996).
	Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," <i>Science</i> 285:260-3 (1999).
	Morimoto et al., "Abnormalities in CD4 ⁺ T-lymphocyte subsets in inflammatory rheumatic diseases," <i>Am. J. Med.</i> 84:817-25 (1988).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.~~ /R.S./

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50474/017002
	Serial No.	10/626,914
	Applicant	Anan Chuntharapai et al.
	Filing Date	July 25, 2003
	Group	1644
	IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Mukhopadhyay et al., "Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor- κ B, and c-Jun NH ₂ -terminal kinase," <i>J. Biol. Chem.</i> 274:15978-81 (1999).
	Nagata and Golstein, "The Fas death factor," <i>Science</i> 267:1449-56 (1995).
	Nagata, "Apoptosis by death factor," <i>Cell</i> 88:355-65 (1997).
	Nardelli et al., "Synthesis and release of B-lymphocyte stimulator from myeloid cells," <i>Blood</i> 97:198-204 (2001).
	Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> 94:6216-21 (1997).
	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>EMBO J.</i> 9:3269-78 (1990).
	Office Action for U.S.S.N. 09/724,341, mailed on June 2, 2003.
	Office Action for U.S.S.N. 09/724,341, mailed on January 30, 2004.
	Office Action for U.S.S.N. 11/069,473, mailed on June 2, 2008.
	Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," <i>FEBS Lett.</i> 424:41-5 (1998).
	Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor," <i>FEBS Lett.</i> 431:351-6 (1998).
	Pan et al., "The receptor for the cytotoxic ligand TRAIL," <i>Science</i> 276:111-3 (1997).
	Pan et al., "An antagonist decoy receptor and a death domain-containing receptor for TRAIL," <i>Science</i> 277:815-8 (1997).
	Patel et al., "Engineering an APRIL-specific B cell maturation antigen," <i>J. Biol. Chem.</i> 279:16727-35 (2004).
	Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> 312:724-9 (1984).
	Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to rituximab," <i>Blood</i> (Abstract 3360) 92(10 Suppl. 1 Pt. 1-2):88b (1998).
	Pitti et al., "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family," <i>J. Biol. Chem.</i> 271:12687-90 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No. 50474/017002
	Serial No. 10/626,914
	Applicant Anan Chuntharapai et al.
	Filing Date July 25, 2003
	Group 1644
	IDS Filed August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer," <i>Nature</i> 396:699-703 (1998).
	Pitzalis et al., "The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion," <i>Eur. J. Immunol.</i> 18:1397-404 (1988).
	Potocnik et al., "Expression of activation antigens on T cells in rheumatoid arthritis patients," <i>Scand. J. Immunol.</i> 31:213-24 (1990).
	Press et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> 69:584-91 (1987).
	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor," <i>Nature</i> 325:593-7 (1987).
	Ravetch and Kinet, "Fc receptors," <i>Annu. Rev. Immunol.</i> 9:457-92 (1991).
	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> 83:435-45 (1994).
	Rennert et al., "A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth," <i>J. Exp. Med.</i> 192:1677-83 (2000).
	Renshaw et al., "Humoral immune responses in CD40 ligand-deficient mice," <i>J. Exp. Med.</i> 180:1889-900 (1994).
	Ridley et al., "Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints," <i>Br. J. Rheumatol.</i> 29:84-8 (1990).
	Scapini et al., "G-CSF-stimulated neutrophils are a prominent source of functional BLYS," <i>J. Exp. Med.</i> 197:297-302 (2003).
	Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor," <i>Cell</i> 61:361-70 (1990).
	Schein, "Production of soluble recombinant proteins in bacteria," <i>Bio-Technol.</i> 7:1141-9 (1989).
	Schiemann et al., "An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway," <i>Science</i> 293:2111-4 (2001).
	Schier et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis," <i>Gene</i> 169:147-55 (1996).
	Schmid et al., "DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant," <i>Proc. Natl. Acad. Sci. USA</i> 83:1881-5 (1986).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Schneider et al., "Characterization of two receptors for TRAIL," <i>FEBS Lett.</i> 416:329-34 (1997).
	Schneider et al., "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth," <i>J. Exp. Med.</i> 189:1747-56 (1999).
	Screaton et al., "LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-9 (1997).
	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," <i>Curr. Biol.</i> 7:693-6 (1997).
	Search Report issued by the Eurasian Patent Office for Eurasian Patent Application No. 200400262, mailed April 14, 2005.
	Seki et al., "Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response," <i>J. Immunol.</i> 148:3093-9 (1992).
	Sheridan et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors," <i>Science</i> 277:818-21 (1997).
	Shields et al., "High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR*," <i>J. Biol. Chem.</i> 276:6591-604 (2001).
	Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," <i>J. Leukocyte Biol.</i> 65:680-3 (1999).
	Shu and Johnson, "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1," <i>Proc. Natl. Acad. Sci. USA</i> 97:9156-61 (2000).
	Simonet et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," <i>Cell</i> 89:309-19 (1997).
	Smith et al., "T2 open reading frame from the Shope Fibroma Virus encodes a soluble form of the TNF receptor," <i>Biochem. Biophys. Res. Commun.</i> 176:335-42 (1991).
	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death," <i>Cell</i> 76:959-62 (1994).
	Smith et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," <i>Cell</i> 73:1349-60 (1993).
	Smith et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," <i>Science</i> 248:1019-23 (1990).
	Somer et al., "Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma," <i>Arthritis Rheum.</i> 49:394-8 (2003).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Srivastava et al., "The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains," <i>Proc. Natl. Acad. Sci. USA</i> 94:13069-74 (1997).
	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> 8:1403-10 (1989).
	Stamenkovic et al., "The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α 2-6 sialyltransferase, CD75, on B cells," <i>Cell</i> 66:1133-44 (1991).
	Stasi et al., "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura," <i>Blood</i> 98:952-7 (2001).
	Supplementary European Search Report for European Patent Application No. 02756618, mailed May 16, 2007.
	Tartaglia et al., "Identification and expression cloning of a leptin receptor, OB-R," <i>Cell</i> 83:1263-71 (1995).
	Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation," <i>J. Immunol.</i> 135:973-9 (1985).
	Tewari and Dixit, "Recent advances in tumor necrosis factor and CD40 signaling," <i>Curr. Opin. Genet. Develop.</i> 6:39-44 (1996).
	Thomas and Quinn, "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium," <i>J. Immunol.</i> 156:3074-86 (1996).
	Thomas et al., "Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells," <i>J. Immunol.</i> 152:2613-23 (1994).
	Thompson et al., "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population," <i>J. Exp. Med.</i> 192:129-35 (2000).
	Thompson et al., "BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF," <i>Science</i> 293:2108-11 (2001).
	Tuscano et al., "Successful treatment of Infliximab-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope Fibroma Virus genome," <i>Virology</i> 160:20-30 (1987).
	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence," <i>Virology</i> 184:370-82 (1991).
	Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C," <i>J. Biol. Chem.</i> 264:11282-7 (1989).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Valentine et al., "Structure and function of the B-cell specific 35-37 kDa CD20 protein," <u>Leukocyte Typing III</u> , McMichael, Ed., Oxford University Press, pps. 440-3 (1987).
	Van Regenmortel, "Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity," <i>Methods</i> 9:465-72 (1996).
	Verma et al., "Rel/NF- κ B/I κ B family: intimate tales of association and dissociation," <i>Gene Dev.</i> 9:2723-35 (1995).
	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> 16:5386-97 (1997).
	Waldschmidt and Noelle, "Long live the mature B cell – a BAFFing mystery resolved," <i>Science</i> 293:2012-3 (2001).
	Wang et al., "TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice," <i>Nat. Immunol.</i> 2:632-7 (2001).
	Ward and Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," <i>Ther. Immunol.</i> 1:165-71 (1994).
	Ware, "APRIL and BAFF connect autoimmunity and cancer," <i>J. Exp. Med.</i> 192:F35-7 (2000).
	Wernick et al., "IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures," <i>Arthritis Rheum.</i> 28:742-52 (1985).
	Wiley et al., "Identification and characterization of a new member of the TNF family that induces apoptosis," <i>Immunity</i> 3:673-82 (1995).
	Wilson et al., "cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions," <i>J. Exp. Med.</i> 173:137-46 (1991).
	Wilson et al., "Genomic structure and chromosomal mapping of the human CD22 gene," 150:5013-24 (1993).
	Wilson-Rawls et al., "The signal-anchor domain of adenovirus E3-6.7 K, a type III integral membrane protein, can direct adenovirus E3-gp19K, a type I integral membrane protein, into the membrane of the endoplasmic reticulum," <i>Virology</i> 201:66-76 (1994).
	Wong et al., "TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor," <i>J. Exp. Med.</i> 186:2075-80 (1997).
	Wong et al., "TRANCE is a TNF family member that regulates dendritic cell and osteoclast function," <i>J. Leukocyte Biol.</i> 65:715-24 (1999).
	Wood et al., "Prolines and amyloidogenicity in fragments of the Alzheimers's peptide β A4," <i>Biochemistry</i> 34:724-30 (1995).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./~~

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50474/017002
	Serial No.	10/626,914
	Applicant	Anan Chuntharapai et al.
	Filing Date	July 25, 2003
	Group	1644
	IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Wu and Wu, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," <i>J. Biol. Chem.</i> 262:4429-32 (1987).
	Wu et al., "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS," <i>J. Biol. Chem.</i> 275:35478-85 (2000).
	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene," <i>Nat. Genet.</i> 17:141-3 (1997).
	Xu et al., "Mice deficient for the CD40 ligand," <i>Immunity</i> 1:423-31 (1994).
	Yan et al., "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency," <i>Curr. Biol.</i> 11:1547-52 (2001).
	Yasuda et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," <i>Endocrinology</i> 139:1329-37 (1998).
	Yelton et al., "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," <i>J. Immunol.</i> 155:1994-2004 (1995).
	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor," <i>J. Exp. Med.</i> 169:1747-56 (1989).
	Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," <i>Nat. Immunol.</i> 1:252-6 (2000).
	Yun et al., "OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40," <i>J. Immunol.</i> 161:6113-21 (1998).
	Zhang et al., "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus," <i>J. Immunol.</i> 166:6-10 (2001).
	Zheng et al., "Induction of apoptosis in mature T cells by tumour necrosis factor," <i>Nature</i> 377:348-51 (1995).

EXAMINER /Ronald Schwadron/	DATE CONSIDERED 11/21/2010
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.~~ /R.S./